In B-cell lymphomas, blood vitamin D levels were shown to affect both the course and progression of the disease by different mechanism of action, such as a possible systemic effects, effects on pharmacokinetics or the activation of the NF-κB pathway [63], and the use of vitamin D treatments increase the expression of some markers, such as CD25, FOXP3, CTLA-4, or PD-1. Here, CTLA4 is linked to B-cell non-Hodgkin lymphoma.